Peptide A · Growth-signaling analogues
Ipamorelin
Synthetic growth hormone secretagogue research material
NNC 26-0161growth hormone secretagogue
Open the 10 mg price board ↗Research price & evidence comparisonIpamorelin
Ipamorelin
vs CJC-1295 no DAC.
Ipamorelin and CJC-1295 no-DAC appear together across many research-catalog searches, but they are not the same seller-labelled material and their published boards use different nominal vial sizes. This page compares current price footprints, vendor overlap, availability, and evidence access while keeping identity and unit boundaries explicit.
1shared seller pages
Different10 mg / 5 mg board sizes
4rows with public evidence routes
0clinical or effect rankings
Identity before price
Two records, kept separate.
Ipamorelin is categorized as a synthetic growth hormone secretagogue research material on a 10 mg board; CJC-1295 no-DAC is categorized as a modified growth hormone-releasing factor analogue research material on a 5 mg board. Shared catalog placement does not create chemical or clinical equivalence.
Peptide B · Growth-signaling analogues
CJC-1295 no DAC
Modified growth hormone-releasing factor analogue research material
Modified GRF 1-29Mod GRF 1-29CJC 1295 without DAC
Open the 5 mg price board ↗Resolve CJC-1295 DAC identity and human evidence ↗Like-for-like fields
Commercial footprint, side by side.
Price ranges use rows marked in stock. “Public evidence route” means a seller exposed a document link; it does not establish authenticity, chain of custody, purity, sterility, or vial contents.
| Comparison field | Ipamorelin | CJC-1295 no DAC |
|---|---|---|
| Editorial family | Growth-signaling analogues | Growth-signaling analogues |
| Seller-listed identity | Synthetic growth hormone secretagogue research material | Modified growth hormone-releasing factor analogue research material |
| Nominal board size | 10 mg | 5 mg |
| Available list range | $54.99–$60.49 | $46.00–$74.79 |
| Median available price | $55.00 | $60.40 |
| Lowest available / mg | $5.50 | $9.20 |
| Available rows | 3 of 3 | 2 of 3 |
| Public evidence routes | 2 rows | 2 rows |
| Evidence only on request | 1 rows | 1 rows |
| Available-price spread | 10% | 63% |
| Snapshot checked | Jul 23, 2026 | Jul 23, 2026 |
Unit warning
Per-milligram figures normalize the seller’s nominal quantity only. They are not a cross-compound value, potency, effect, or dose comparison.
Seller overlap
Where the current boards intersect.
The pair is commonly cross-shopped in online research catalogs, making it useful to compare commercial coverage while explicitly refusing the stack, protocol, dosage, or outcome claims that often accompany the search.
- Pepta Labs
- Prime Peptides
- Purgo Labs
- Biotech Peptides
- Core Peptides
Three reading rules
What keeps this comparison honest.
- 01
Normalize prices to each board’s stated milligrams before reading the commercial spread.
- 02
Keep the secretagogue and growth hormone-releasing factor analogue labels distinct on every seller, price, and evidence row.
- 03
Seller combination claims and personal-use protocols are not evidence inputs on Peptide Local.
Official context boundary
Read the source behind each category note.
These official context records explain why Peptide Local keeps research listings outside medical and approved-product lanes. They do not certify any seller or material.
FDA says compounded drugs containing ipamorelin acetate may pose immunogenicity and peptide-impurity risks, notes characterization complexity, and says important route-specific safety information is lacking.
Read the FDA source ↗FDA lists CJC-1295 among bulk substances that may present significant safety risks in compounding and describes limited clinical safety information. This board is specifically for seller-labelled 5 mg no-DAC or Modified GRF (1-29) research material.
Read the FDA source ↗Continue comparing